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Abstract
Background: Hypertension affects about 10 % of pregnancies and is responsible for both maternal and neonatal
devastating complications such as eclampsia, HELLP syndrome, prematurity and maternal and neonatal death.
The resolution of the disease occurs in the first twelve weeks postpartum. The behavior of blood pressure and
occurrence of very high blood pressure episodes among women with severe preeclampsia is related to remodeling
of the dynamics of body fluids with consequent increase in intravascular volume. The persistence of hypertension
in critical levels results in increased puerperal morbidity.
Objectives: To evaluate the effectiveness of furosemide in accelerating blood pressure recovery among women
with severe preeclampsia.
Methods/design: A triple-masked placebo controlled clinical trial, will be conducted including 120 postpartum
women with severe preeclampsia, after eclampsia prophylaxis with magnesium sulfate and with adequate diuresis.
Women with chronic hypertension and users of diuretics will be deleted. Informed consent will be obtained from
all participants. Patients will be randomized to receive furosemide (40 mg orally every twenty four hours) or
placebo. The variables are systolic and diastolic blood pressure, frequency of hypertensive crises, need for
maintenance of antihypertensive therapy, number of antihypertensive agents used to control blood pressure, urine
output, length of hospital stay, adverse effects and maternal complications. This study was approved by the
Research Ethics Committee in humans of our institution. All participants will be duly informed about the aims of
the project and will be included only if they agree to participate voluntarily, signing the informed consent.
Trial registration: This study was registered on Clinical Trials.gov under the number NCT02163655.
(http://clinicaltrials.gov/show/NCT02163655).
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Introduction
Hypertension in pregnancy continues to represent a real
public health issue. Affecting 10 % of all pregnancies [1],
hypertension is the first cause of maternal death in
Brazil http://inseer.ibict.br/rbsp/index.php/rbsp/article/
viewFile/474/pdf_150 and the second cause in the world
[2, 3]. Worldwide, more than 99 % of cases of maternal
deaths related to hypertension occur in low-income coun-
tries, reflecting not only a higher incidence as the lack of
prenatal care and adequate treatment of obstetric emer-
gencies [2]. Moreover, it is an important potentially life-
threatening condition of life and cause of maternal near
miss [4], along with increased perinatal morbidity and
mortality [2]. It is also associated with long-term compli-
cations, with increased risk of cardiovascular disease in af-
fected women [5, 6].
Among hypertensive disorders complicating preg-
nancy, pre-eclampsia and eclampsia represent the most
severe conditions [7, 8]. Associated maternal risks include
abruptio placentae, convulsions, acute pulmonary edema,
convulsions, acute kidney injury and death. Perinatal risks
are due to the reduction in the utero-placental blood flow
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and are represented by fetal growth restriction, hypoxia
and fetal death, prematurity and its complications, among
which the most important is the respiratory distress
syndrome of the newborn [9].
It is well known that magnesium sulfate is the most
effective and safe drug for preventing and treating eclamp-
tic seizures and should be administered to all women in
whom there is concern about eclampsia or eclampsia risk
[10–14]. Magnesium sulfate significantly reduces ma-
ternal death when used to treat eclampsia and is a
real "evidence-based solution" http://www.engenderhealth.
org/files/pubs/maternal-health/engenderhealth-eclampsia-
report.pdf. The only definitive treatment is delivery, and
the resolution of pregnancy is indicated in all cases of
eclampsia regardless of gestational age [9] in cases of pre-
eclampsia at ≥ 34 weeks [9, 15, 16] and mild preeclampsia
cases without other complications at ≥ 37 weeks [17].
However, even after birth and with appropriate treat-
ment, concern about the complications of disease per-
sist, since this condition can take days or weeks to
resolve. In the postnatal period, with the return of liquid
from the interstitial and extravascular compartment to
the intravascular, very high blood pressure episodes are
common and the persistence of hypertension in critical
levels results in increased puerperal morbidity. Thus,
blood pressure levels may continue to rise, which most
often occurs in the first five days after birth, reaching a
peak between three to six days after delivery [18]. New
onset postpartum hypertension and preeclampsia can
occur, with a frequency ranging from 0,3 %-27,5 % [19].
Complications of severe hypertension include stroke,
eclampsia, congestive heart failure, acute pulmonary
edema, renal failure and death [20].
Besides the mobilization of liquid from the interstiti-
cial and intravascular to extravascular space correspond-
ing to six to eight liters of the total body water, there is
also a return of 950 mEq of total body sodium accumu-
lated during pregnancy. It is observed increased urinary
sodium excretion between three and five days after birth
[21] possibly due to the increase of atrial natriuretic pep-
tide in the first week after delivery, which has a role in
natriuresis and entails inhibition of aldosterone, angio-
tensin II and vasopressin [22]. Several approaches have
been proposed to accelerate the postpartum maternal re-
covery, but the effectiveness of these approaches as well
as the ideal antihypertensive treatment in the postpar-
tum period, remain to be established. Furosemide use
has been proposed with this goal. Patients with pre-
eclampsia and eclampsia may experience persistent
hypertension after delivery, in response to the mobili-
zation of interstitial and extravascular fluid into the
intravascular space, the excess of total body water and
inadequate secretion of sodium due to reduced glome-
rular filtration [23]. This is an important rationale for
furosemide therapy since by its mechanism of action,
this loop diuretic can act in patients with fluid overload,
eliminating the intravascular fluid that has been mobi-
lized in the postpartum period and thereby reducing
blood volume and blood pressure and also reducing the
need of antihypertensive therapy [23]. This therapy is
logical when considering the pathophysiology of postpar-
tum hypertension, with the objective of maintain a low
central venous pressure and pulmonary capillary wedge
pressures, raising colloid osmotic pressure and preventing
the development of pulmonary edema and congestive
heart failure [24].
In the systematic Cochrane Review that evaluated pre-
vention and treatment of postpartum hypertension were
included nine randomized clinical trials, of which two
trials (282 women included) assessed postnatal furosem-
ide at a dosage of 20-40 mg orally daily), compared with
placebo or no treatment [25]. One trial added potassium
supplementation (20 mEq orally daily) [23] and in the
other [26] women at “high risk” of eclampsia also re-
ceived magnesium sulfate. None of the studies reported
the mean and standard deviation of the baseline blood
pressure but one trial [26] reported a greater decrease in
blood pressure in the group receiving furosemide com-
pared to placebo. In the group receiving furosemide it
was reported a change of blood pressure on days one,
three and seven after delivery (i.e., −6.5 mmHg (furosem-
ide) versus −3.5 (placebo) on day one, −10.6 (furosemide)
versus −9.75 (placebo) on day three, and −11.5 (furosem-
ide) versus −7.8 (placebo) on day seven). In the other trial
[23] including 264 women, only postpartum patients with
severe preeclampsia (n = 70) who received furosemide
compared with controls had significantly lower systolic
blood pressure by postpartum day 2 (142 +/− 13 mmHg
compared with 153+/−19 mmHg, P < .004) and required
less antihypertensive therapy during hospitalization (14 %
compared with 26 %, p = 0.371) and at discharge (6 %
compared with 26 %, P = 0.045). Follow-up ranged from
day 10 postpartum [23] to six weeks postpartum [26].
The reviewers conclude that reliable data are not avail-
able to guide management of women with postpartum
hypertension. For women with pre-eclampsia, postnatal
furosemide may decrease the need for postnatal anti-
hypertensive therapy in hospital, but more data are
needed on substantive outcomes before this practice
can be recommended. Notwithstanding, the optimal
management of postpartum hypertension is not yet well
established.
Thus, to determine the potential benefit of using
diuretics in women with preeclampsia is an important
issue in modern obstetrics. This study will be carried out
with the objective of determining the effectiveness of
furosemide to accelerate the recovery of hypertension in
postpartum patients with severe preeclampsia.
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Objectives and hypothesis
The overall objective is to determine the effectiveness of
furosemide to accelerate the recovery of hypertension in
postpartum patients with severe preeclampsia in a ran-
domized clinical trial.
The hypothesis is that mean daily average systolic,
diastolic and mean arterial pressure (MAP) and the
frequency of very high blood pressure episodes when
furosemide is administered is lower.
Specific objectives
In patients with severe preeclampsia receiving furosemide
or placebo in postpartum, compare:
Primary outcomes
 Daily average of systolic, diastolic and mean arterial
pressure (MAP);
 Heart rate;
 Frequency of very high blood pressure episodes.
Secondary maternal outcomes
 Control of blood pressure;
 Frequency of use of antihypertensive agent for the
treatment of hypertensive crisis;
 Need for maintenance of antihypertensive therapy
for blood pressure control;
 Number of antihypertensive agents used to control
blood pressure at hospital discharge;
 Time until blood pressure control;
 Daily urine output;
 Reduction of edema;
 Length of hospital stay;
 Adverse effects: hypokalemia, polydipsia, headaches,
mental confusion, muscle aches, tetany, muscle
weakness, heart rhythm disturbances and
gastrointestinal symptoms;
 Frequency of maternal complications:
imminent eclampsia, eclampsia, infection,
bleeding manifestations, shock and maternal
death.
Main hypothesis
In women randomized to postpartum oral furosemide,
in comparison to placebo:
 Daily averages of systolic, diastolic and mean arterial
pressure (MAP) are lower, heart rate is the same and
the frequency of very high blood pressure episodes
is lower.
 Control of blood pressure is obtained earlier;
 Frequency of use of antihypertensive agent for the
treatment of hypertensive crisis is lower, as well as
the need for maintenance of antihypertensive
therapy for blood pressure control;
 Fewer antihypertensive agents are needed in order
to control blood pressure at hospital discharge;
 Time until blood pressure control is lower;
 Daily urine output is higher;
 Reduction of edema is obtained in less time;
 Length of hospital stay is reduced.
Methods/design
Study design
The present study is a triple masked randomized con-
trolled trial.
Study population and location
The study population will comprehend all women hos-
pitalized in IMIP during the data collection period with
the diagnosis of preeclampsia/eclampsia.
Eligibility criteria
Postpartum women diagnosed with severe preeclampsia,
after completion of therapy with magnesium sulfate,
with spontaneous diuresis and greater than 50 ml/h.
Women with superimposed preeclampsia, or that used
diuretics before admission to the intensive care unit
(ICU), with acute or chronic kidney disease, diabetes
mellitus; collagen disease; sickle cell anemia, patients
with hemodynamic instability or with hypokalemia (K <
3.0 mEq/L) or patients with contraindications to the use
of furosemide or unable to consent were excluded.
Procedures for selecting participants and randomization
Eligible patients in labor will be invited to participate
and those who agree and sign the informed consent
form will be included in the study and then will be allo-
cated to either using furosemide or placebo according to
a random list of numbers generated by the Random
Allocation Software Ispharan Iran, version 1.0. This list
of randomization will be provided by the statistician to
the pharmacist who will be responsible for preparing the
packages containing either the furosemide or placebo,
both in an identical presentation, with the identification
number of list labeled. This procedure will be followed
in order to guarantee the concealment of allocation of
patients in both arms. Both patients and medical staff
should be blind of the intervention condition in each
case. Study medication and placebo, after delivered by
the pharmaceutical industry to the pharmacy, will be
packed as previously described and according the ran-
dom list. The pharmacy will be responsible for sending
sets to the ICU were the nurse in charge will keep all
the packages until the administration of the drug to the
patient according to the patients’ enrollment. The subjects
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will receive the study medication every 24 hours for a
maximum of five days.
During the observation period the women will be
subject to strict control of blood pressure, urine output
(diuresis evaluated spontaneous or urinary catheter) and
weight control. The routine management adopted at the
hospital will be followed and other hypertensive agents
will be initiated and chose according to the attending
clinician's discretion.
Sample size calculation
The calculation of sample size was done in the online
public domain software version 2.3 Openepi (Atlanta,
GA). Were used as reference data found in clinical trial
using furosemide versus placebo, in which they found an
average systolic blood pressure of 142 mmHg and a
standard deviation of 13 mmHg and 153 mmHg and a
standard deviation of 19 mmHg, respectively. For a
power of 90 % and a significance level of 5 %, 94 patients
would be needed in both groups to highlight this dif-
ference. In anticipation of possible post-randomization
losses added up to total 20 % of patients, resulting in





Daily maximum systolic blood pressure; daily maximum
diastolic blood pressure; maximum average daily blood
pressure; heart rate; frequency of very high blood pres-
sure episodes; control of blood pressure; need for main-
tenance of antihypertensive therapy for blood pressure
control; number of antihypertensive agents used to con-
trol blood pressure; time required for recovery of blood
pressure; urinary output; length of hospital stay; adverse
effects (polydipsia, headache, confusion, muscle aches,
tetany, muscle weakness, heart rhythm disturbances,
gastrointestinal symptoms); puerperal complications dur-
ing hospitalization (acute pulmonary edema, hemorrhagic
manifestations, imminent eclampsia, eclampsia, maternal
death, shock, persistent edema.
Main outcomes
 Systolic blood pressure (SBP): Determined by the
appearance of the first sound of Korotkoff.
Continuous quantitative variable, expressed in
millimeters of mercury (mmHg).
 Diastolic Blood Pressure (DBP): Determined by the
appearance of the fifth Korotkoff sound. Continuous
quantitative variable, expressed in millimeters of
mercury (mmHg).
 Mean arterial pressure (MAP): The value of mean
arterial pressure in mmHg. Will be calculated by the
formula: systolic blood pressure (SBP) plus twice the
diastolic blood pressure (DBP) divided by three,
being represented by (+2PAD SBP)/3. Continuous
quantitative variable, expressed in millimeters of
mercury (mmHg).
 Heart rate: Refers to the number of heart beats per
minute, measured at least four times daily.
 Frequency of very high blood episodes:
Defined as the daily number of very high blood
pressure episodes, defined as Systolic blood
pressure ≥ 180 mmHg or Diastolic blood
pressure ≥ 110 mmHg.
 Control of blood pressure: Defined < 140 mmHg of
systolic blood pressure and < 90 mmHg of diastolic
blood pressure at all measurements (at least four)
for a minimum 24-hour.
 Need for maintenance of antihypertensive therapy
for blood pressure control: Use of anti-hypertensive
agents for blood pressure control.
 Number of antihypertensive agents used to control
blood pressure: Number of antihypertensive agents
used to control blood pressure.
 Time required for recovery of blood pressure: Time
to achieve control of blood pressure expressed in
whole numbers.
 Hospital stay: For time elapsed between the
beginning of inpatient treatment with furosemide or
placebo until discharge.
 Daily urine output: Defined as the average amount
of urine excreted, expressed in milliliters (ml),




For data collection, a pre-coded standard form will be
used for data entry on the computer. After identifying
the patients who are according to the eligibility criteria,
using a specific check list, and who agree to participate
in the study and sign the informed consent form, infor-
mation will be collected and filled in the form. The
checklist, as well as the form will be completed by the
researchers.
Upon completion, the forms will be rigorously reviewed
by the researchers to cross-check the information col-
lected with the information contained in the records.
Procedures for quality control, such as reviewing the com-
pleted forms and check manually typing will be adopted.
A first quality control of data collection should be done
before and during the typing of electronic records, to
identify possible inconsistencies in the data researcher.
The second quality control will check the compatibility
Cursino et al. Reproductive Health  (2015) 12:66 Page 4 of 7
between the physical archived records and data contained
in electronic forms. The data will be entered in a specific
database, created using the Epi Info statistical program
7.1.4 or an updated version available at this time. Each
month the database will be reviewed by the principal in-
vestigator, getting listing of variables and correcting any
inconsistencies or missing information from the query to
the forms.
Data analysis plan
The data analysis will be performed using the public do-
main software Epi Info version 7.1.4 (Centers for Disease
Control and Prevention, Atlanta, GA), or the newest avail-
able version at the time of analysis) under the intention to
treat principle.
The statistician will remain blind to the meaning of
the Groups A or B to which patients are allocated until
the tables and the analysis concluded. The approach for
analysis will be that showed in Fig. 1 using an intention-to-
treat strategy and following the correspondent recommen-
dations from the CONSORT statement [11].
The characteristics of the participants in each group
will be compared with Student’s t test for continuous
variables with normal distribution and Mann–Whitney
U test for discrete and ordinal variables or those with
non-normal distribution. Categorical variables will be
compared with Pearson’s χ [2] test or Fisher’s exact test,
as appropriate. P values for all tests will be two tailed at
a 5 % level of significance.
Risk ratios and their 95 % confidence intervals will be
calculated as a measure of relative risk. The number
needed to treat (NNT) and its 95 % confidence interval
will be calculated for the outcomes in which a beneficial
effect of using furosemide is achieved, using the EBM
calculator [http://moosenose.com/EBCalculator.htm]; in
case of adverse effects the number needed to harm
(NNH) and its 95 % confidence will also be calculated.
Quality control
The researchers will maintain a record of problems oc-
curred during the study and any doubt should be solved
with the Steering Committee.
Ethical issues
The original protocol of this research proposal has already
obtained approval of the local Institutional Review Board
from the coordinating center (IMIP, Recife, Brazil), and of
the National Committee for Ethics in Research (CONEP)
of the Brazilian Ministry of Health, under the number
3957. The protocol also was published in the Clinical
Trials Register under the number NCT02163655. (https://
clinicaltrials.gov/ct2/show/NCT02163655).
Patients will only be included if they agree to parti-
cipate and sign the informed consent. All principles
Fig. 1 Study design and population (CONSORT, 2010) [27]
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related to research in human beings established by the
Brazilian National Health Council according to the
Declaration of Helsinki will be followed. The confidential-
ity on women’s data and medical care will be ensured
regardless of whether they participate in the study or not.
Discussion
Technical and scientific contributions of the study
Treatment of patients with preeclampsia and eclampsia
still represents a challenge in the postpartum period,
since the pressure levels may continue to rise, which
increases morbidity, mortality and length of hospital
stay. There is a rationale for the use of furosemide for
the purpose to reduce these complications since this
drug eliminates excess intravascular volume resulting
from the mobilization of liquid which was previously in
the interstitial and extravascular space. However, evi-
dence from randomized clinical trials is scarce and insuf-
ficient for a recommendation to incorporate the use of
furosemide in daily clinical practice.
Furosemide, a loop diuretic, is a cheap drug, safe, widely
available and considered level 1 for use during breastfeed-
ing, especially if used for shorter periods. Long-term treat-
ment may inhibit lactation but is not the case of this
proposed therapy, using low dose of only five days after
birth. If it is demonstrated its effectiveness in reducing
blood pressure levels, the need for antihypertensive drugs
and shortening of hospitalization, significant benefits can
be obtained for women with pre-eclampsia and the health
system. With the reduction in blood pressure and the
elimination of excess intravascular, the incidence of acute
pulmonary edema and other diseases resulting from fluid
overload can be decreased. The reduced need for antihy-
pertensive drugs, beyond avoiding side effects for women,
can along with the reduction of hospital days, lead to sub-
stantial savings for the health system.
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